Latest news

Swissmedic grants Debiopharm marketing authorisation for Moapar® – A new therapeutic avenue for the treatment of sexual deviations

Salvacyl®, developed by Debiopharm, is launched in two European countries – a new therapeutic avenue for the treatment of sexual…

Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development…

DiagnoSwiss remporte le “Prix Debiopharm Valais pour les Sciences de la Vie” pour sa technologie de bio-micro-électronique innovante

Debiopharm and Mepha sign distribution agreement for Pamorelin® LA 1-3- and 6-month formulations – a new treatment for prostate cancer…

Clinical Update – Debio 025 in Hepatitis C – Debiopharm starts phase IIb study after record time patient randomisation

Clinical Update – Debio 025 in Hepatitis C – Debiopharm presents promising phase IIa results showing potent antiviral activity

Bachem and Debiopharm sign follow-up contract for long-term supply of Triptorelin Pamoate

Clinical Update – Debio 025 in Hepatitis C – Debiopharm starts phase IIb triple therapy study, a promising therapeutic avenue